SCHEDULE 13G: Anson Funds Discloses 9.6% Passive Stake in Oncolytics Biotech

Anson Funds Management LP and its affiliates have reported a passive beneficial ownership of 9.6% in Oncolytics Biotech, Inc., totaling 8,185,743 shares.

Summary

• Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo, and Mr. Moez Kassam collectively reported beneficial ownership of 8,185,743 shares of Oncolytics Biotech, Inc. Common Stock.
• This ownership represents 9.6% of the outstanding class of Common Stock.
• The calculation of the percentage is based on 8,185,743 shares beneficially owned divided by a total of 85,171,776 shares, which includes 76,986,033 shares issued and outstanding as of August 8, 2024, and 8,185,743 shares receivable upon exercise of warrants.
• The reporting persons hold shared voting and dispositive power over all 8,185,743 shares.
• The filing is a Schedule 13G, indicating a passive investment purpose, meaning the reporting persons do not intend to change or influence the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as a significant passive stake by an institutional investor can be interpreted as a vote of confidence in the company's long-term prospects, although the filing itself is purely informational.

Positives

• The disclosure of a significant 9.6% stake by Anson Funds, a notable investment firm, may be perceived by the market as a vote of confidence in Oncolytics Biotech, Inc.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Oncolytics Biotech, Inc.'s future performance or strategic direction. It solely reports a passive beneficial ownership stake.

Industry Context

This filing indicates a significant institutional investment in a biotechnology company. Such investments are common in the biotech sector, where firms often seek to capitalize on potential future drug development successes. The passive nature of the stake suggests a long-term investment perspective rather than an activist intent.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor may positively influence market perception and potentially the share price, signaling confidence in the company.

Key Dates

Keywords

Oncolytics Biotech, Anson Funds, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Biotech, Healthcare, Institutional Investor